Status:
COMPLETED
A Phase 2 Study Of The 24-Hour Intraocular Pressure Lowering And Systemic Exposure Of PF-04217329
Lead Sponsor:
Pfizer
Conditions:
Glaucoma, Open-Angle
Ocular Hypertension
Eligibility:
All Genders
18-99 years
Phase:
PHASE2
Brief Summary
This study will characterize the effect of PF-04217329, alone and in combination with latanoprost, on circadian intraocular pressure and blood pressure in glaucoma patients. Blood samples will be coll...
Eligibility Criteria
Inclusion
- Diagnosis of primary open-angle glaucoma or ocular hypertension in one or both eyes
- Intraocular Pressure (IOP) of at least 22 mmHg and not more than 30 mmHg in either eye at 8 AM after discontinuing previous glaucoma treatment
- Visual acuity correctable to 20/100 or better in each eye.
Exclusion
- Closed/barely open anterior chamber angle or a history of acute angle closure in either eye.
- Diagnosis of a clinically significant or progressive retinal disease (eg, diabetic retinopathy, macular degeneration) in either eye.
- Advanced glaucoma or a history of severe central visual field loss in either eye.
- History of ocular surgery or trauma in either eye within 6 months of the screening visit.
- History of ocular infection, ocular inflammation, or laser surgery in either eye within 3 months of the screening visit.
Key Trial Info
Start Date :
January 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2010
Estimated Enrollment :
31 Patients enrolled
Trial Details
Trial ID
NCT00934089
Start Date
January 1 2010
End Date
June 1 2010
Last Update
May 3 2021
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
West Coast Clinical Trials, LLC
Cypress, California, United States, 90630
2
Glory Medical Group
Garden Grove, California, United States, 92844
3
East-West Eye Institute
Gardena, California, United States, 90247
4
Ophthalmology Corporation
Long Beach, California, United States, 90806